|
1
|
Tostain J, Li G, Gentil-Perret A and
Gigante M: Carbonic anhydrase 9 in clear cell renal cell carcinoma:
A marker for diagnosis, prognosis and treatment. Eur J Cancer.
46:3141–3148. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Hadoux J, Vignot S and De La Motte Rouge
T: Renal cell carcinoma: Focus on safety and efficacy of
temsirolimus. Clin Med Insights Oncol. 4:143–154. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Su Z, Chen D, Zhang E, Li Y, Yu Z, Shi M,
Jiang Z, Ni L, Yang S, Gui Y, et al: MicroRNA-509-3p inhibits
cancer cell proliferation and migration by targeting the
mitogen-activated protein kinase kinase kinase 8 oncogene in renal
cell carcinoma. Mol Med Rep. 12:1535–1543. 2015.PubMed/NCBI
|
|
4
|
Alt AL, Boorjian SA, Lohse CM, Costello
BA, Leibovich BC and Blute ML: Survival after complete surgical
resection of multiple metastases from renal cell carcinoma. Cancer.
117:2873–2882. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Rasmussen F: Metastatic renal cell cancer.
Cancer Imaging. 13:374–380. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Zou X, Zhong J, Li J, Su Z, Chen Y, Deng
W, Li Y, Lu S, Lin Y, Luo L, et al: miR-362-3p targets nemo-like
kinase and functions as a tumor suppressor in renal cancer cells.
Mol Med Rep. 13:994–1002. 2016.PubMed/NCBI
|
|
7
|
Jiang JX, Gao S, Pan YZ, Yu C and Sun CY:
Overexpression of microRNA-125b sensitizes human hepatocellular
carcinoma cells to 5-fluorouracil through inhibition of glycolysis
by targeting hexokinase II. Mol Med Rep. 10:995–1002.
2014.PubMed/NCBI
|
|
8
|
Akman HB, Selcuklu SD, Donoghue MT,
Akhavantabasi S, Sapmaz A, Spillane C, Yakicier MC and Erson-Bensan
AE: ALCAM is indirectly modulated by miR-125b in MCF7 cells. Tumour
Biol. 36:3511–3520. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Yang Q, Wang Y, Lu X, Zhao Z, Zhu L, Chen
S, Wu Q, Chen C and Wang Z: MiR-125b regulates
epithelial-mesenchymal transition via targeting Sema4C in
paclitaxel-resistant breast cancer cells. Oncotarget. 6:3268–3279.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wei X, Chen D, Lv T, Li G and Qu S: Serum
microRNA-125b as a potential biomarker for glioma diagnosis. Mol
Neurobiol. 53:163–170. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Iwamoto H, Kanda Y, Sejima T, Osaki M,
Okada F and Takenaka A: Serum miR-210 as a potential biomarker of
early clear cell renal cell carcinoma. Int J Oncol. 44:53–58.
2014.PubMed/NCBI
|
|
12
|
Karbasy SH, Taheriazam A, Mirghasemi A,
Sedaghati F, Shakeri M, Yahaghi E and Bahador R: RETRACTED ARTICLE:
Upregulation of miR-300 and downregulation of miR-125b act as
potential predictor biomarkers in progression, metastasis, and poor
prognosis of osteosarcoma. Tumour Biol. Sep 2–2015.(Epub ahead of
print). PubMed/NCBI
|
|
13
|
Tsang FH, Au V, Lu WJ, Shek FH, Liu AM,
Luk JM, Fan ST, Poon RT and Lee NP: Prognostic marker microRNA-125b
inhibits tumorigenic properties of hepatocellular carcinoma cells
via suppressing tumorigenic molecule eIF5A2. Dig Dis Sci.
59:2477–2487. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
He H, Xu F, Huang W, Luo SY, Lin YT, Zhang
GH, Du Q and Duan RH: miR-125a-5p expression is associated with the
age of breast cancer patients. Genet Mol Res. 14:17927–17933. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wang F, Yu D, Liu Z, Wang R, Xu Y, Cui H
and Zhao T: miR-125b functions as a tumor suppressor and enhances
chemosensitivity to cisplatin in osteosarcoma. Technol Cancer Res
Treat. 15:NP105–NP112. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wu JG, Wang JJ, Jiang X, Lan JP, He XJ,
Wang HJ, Ma YY, Xia YJ, Ru GQ, Ma J, et al: MiR-125b promotes cell
migration and invasion by targeting PPP1CA-Rb signal pathways in
gastric cancer, resulting in a poor prognosis. Gastric Cancer.
18:729–739. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Fu Q, Liu Z, Pan D, Zhang W, Xu L, Zhu Y,
Liu H and Xu J: Tumor miR-125b predicts recurrence and survival of
patients with clear-cell renal cell carcinoma after surgical
resection. Cancer Sci. 105:1427–1434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Li Q, Han Y, Wang C, Shan S, Wang Y, Zhang
J and Ren T: MicroRNA-125b promotes tumor metastasis through
targeting tumor protein 53-induced nuclear protein 1 in patients
with non-small-cell lung cancer. Cancer Cell Int. 15:842015.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Liu H, Brannon AR, Reddy AR, Alexe G,
Seiler MW, Arreola A, Oza JH, Yao M, Juan D, Liou LS, et al:
Identifying mRNA targets of microRNA dysregulated in cancer: With
application to clear cell renal cell carcinoma. BMC Sys Biol.
4:512010. View Article : Google Scholar
|
|
21
|
He H, Wang L, Zhou W, Zhang Z, Wang L, Xu
S, Wang D, Dong J, Tang C, Tang H, et al: MicroRNA expression
profiling in clear cell renal cell carcinoma: Identification and
functional validation of key miRNAs. PLoS One. 10:e01256722015.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Juan D, Alexe G, Antes T, Liu H,
Madabhushi A, Delisi C, Ganesan S, Bhanot G and Liou LS:
Identification of a microRNA panel for clear-cell kidney cancer.
Urology. 75:835–841. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Heinzelmann J, Henning B, Sanjmyatav J,
Posorski N, Steiner T, Wunderlich H, Gajda MR and Junker K:
Specific miRNA signatures are associated with metastasis and poor
prognosis in clear cell renal cell carcinoma. World J Urol.
29:367–373. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lee M, Kim EJ and Jeon MJ: MicroRNAs 125a
and 125b inhibit ovarian cancer cells through post-transcriptional
inactivation of EIF4EBP1. Oncotarget. 7:8726–8742. 2016.PubMed/NCBI
|
|
25
|
Tsang FH, Au SL, Wei L, Fan DN, Lee JM,
Wong CC, Ng IO and Wong CM: Long non-coding RNA HOTTIP is
frequently up-regulated in hepatocellular carcinoma and is targeted
by tumour suppressive miR-125b. Liver Int. 35:1597–1606. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Wu S, Liu F, Xie L, Peng Y, Lv X, Zhu Y,
Zhang Z and He X: miR-125b suppresses proliferation and invasion by
targeting MCL1 in gastric cancer. Biomed Res Int. 2015:3652732015.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zang B, Huang G, Wang X and Zheng S:
HPV-16 E6 promotes cell growth of esophageal cancer via
downregulation of miR-125b and activation of Wnt/β-catenin
signaling pathway. Int J Clin Exp Pathol. 8:13687–13694.
2015.PubMed/NCBI
|
|
28
|
Wang X, Zhang Y, Fu Y, Zhang J, Yin L, Pu
Y and Liang G: MicroRNA-125b may function as an oncogene in lung
cancer cells. Mol Med Rep. 11:3880–3887. 2015.PubMed/NCBI
|
|
29
|
Wang M, Zhu X, Sha Z, Li N, Li D and Chen
L: High expression of kinesin light chain-2, a novel target of
miR-125b, is associated with poor clinical outcome of elderly
non-small-cell lung cancer patients. Br J Cancer. 112:874–882.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Lehmann TP, Korski K, Gryczka R, Ibbs M,
Thieleman A, Grodecka-Gazdecka S and Jagodziński PP: Relative
levels of let-7a, miR-17, miR-27b, miR-125a, miR-125b and miR-206
as potential molecular markers to evaluate grade, receptor status
and molecular type in breast cancer. Mol Med Rep. 12:4692–4702.
2015.PubMed/NCBI
|
|
31
|
Vilquin P, Donini CF, Villedieu M, Grisard
E, Corbo L, Bachelot T, Vendrell JA and Cohen PA: MicroRNA-125b
upregulation confers aromatase inhibitor resistance and is a novel
marker of poor prognosis in breast cancer. Breast Cancer Res.
17:132015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen H and Xu Z:
Hypermethylation-associated silencing of miR-125a and miR-125b: A
potential marker in colorectal cancer. Dis Markers.
2015:3450802015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yamada A, Horimatsu T, Okugawa Y, Nishida
N, Honjo H, Ida H, Kou T, Kusaka T, Sasaki Y, Yagi M, et al: Serum
miR-21, miR-29a, and miR-125b are promising biomarkers for the
early detection of colorectal neoplasia. Clin Cancer Res.
21:4234–4242. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Ribeiro J, Marinho-Dias J, Monteiro P,
Loureiro J, Baldaque I, Medeiros R and Sousa H: miR-34a and
miR-125b expression in HPV infection and cervical cancer
development. Biomed Res Int. 2015:3045842015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Chen X, Liu J, Feng WK, Wu X and Chen SY:
MiR-125b protects against ethanol-induced apoptosis in neural crest
cells and mouse embryos by targeting Bak 1 and PUMA. Exp Neurol.
271:104–111. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Xie X, Hu Y, Xu L, Fu Y, Tu J, Zhao H,
Zhang S, Hong R and Gu X: The role of
miR-125b-mitochondria-caspase-3 pathway in doxorubicin resistance
and therapy in human breast cancer. Tumour Biol. 36:7185–7194.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Morelli E, Leone E, Cantafio ME, Di
Martino MT, Amodio N, Biamonte L, Gullàà A, Foresta U, Pitari MR,
Botta C, et al: Selective targeting of IRF4 by synthetic
microRNA-125b-5p mimics induces anti-multiple myeloma activity in
vitro and in vivo. Leukemia. 29:2173–2183. 2015. View Article : Google Scholar : PubMed/NCBI
|
